Aicardi-Goutières Syndrome (AGS) Research
1 - 5 of 5
Our experts work hand-in-hand with the Global Leukodystrophy Initiative, establishing collaborative research partnerships to foster breakthroughs.
Individuals with a confirmed diagnosis of Aicardi-Goutières syndrome (AGS) may be eligible for a compassionate use study of baricitinib, a JAK 1/2-inhibitor.
If your child has had an MRI in the past two months demonstrating white matter abnormalities, but no diagnosis, they may be eligible for the LeukoSEQ study.
The Myelin Disorders Biorepository Project (MDBP) collects and analyzes data from leukodystrophy patients worldwide to support ongoing and future scientific research.